fbbva-16-biodiversidad-charpentier

Emmanuelle Charpentier

FRONTIERS OF KNOWLEDGE LAUREATE

Biomedicine

9th edition

The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category is shared, in this ninth edition, by Emmanuelle Charpentier, Jennifer Doudna and Francisco Martínez Mojica, for creating the CRISPR/Cas9 genome editing techniques that have triggered a revolution in biology, equipping laboratories with a powerful tool to understand gene function and biological systems, and as a way to treat disease.

CITATION (EXCERPT)

The BBVA Foundation Frontiers of Knowledge Award in Biomedicine goes, in this ninth edition, to Emmanuelle Charpentier, Jennifer Doudna and Francisco J. Martínez Mojica, for work that led to the revolution in biology permitted by CRISPR/Cas9 techniques.

Martínez Mojica identified CRISPR sequences in bacteria and postulated their role as an adaptive defense system against viruses; Charpentier and Doudna elucidated the molecular mechanism of CRISPR/Cas9 action and demonstrated its potential use as a universal tool for genome editing, paving the way for a multitude of applications in essentially any organism.

Genome editing involves the cutting of DNA at a designated location and its subsequent repair by the cell’s own machinery, which can be harnessed to make precise mutations, to add sequences or to substitute one sequence for another. The simplicity and versatility of the CRISPR/Cas9 system have led to its rapid adoption in laboratories throughout the world as a tool to understand gene function and biological systems, and as a way to treat disease.

BIO

Emmanuelle Charpentier (Juvisy-sur-Orge, France; 1968) studied biochemistry and microbiology at the Université Pierre et Marie Curie in Paris before completing a PhD in Microbiology at Institut Pasteur. From 1996 to 2002, she continued her training at the Rockefeller University, New York University Langone Medical Center and the Skirball Institute of Biomolecular Medicine (all in New York) and at St Jude Children’s Research Hospital in Memphis, Tennessee.

She then returned to Europe to establish her own research group at the Max F. Perutz Laboratories of the University of Vienna, and later took up the post of Associate Professor in the Laboratory for Molecular Infection Medicine Sweden at the University of Umeå (Sweden), where she was also Visiting Professor in the Umeå Centre for Microbial Research.

In 2013, she was awarded a professorship at the Helmholtz Centre for Infection Research, Braunschweig, and in 2014 became Alexander von Humboldt Professor at Hannover Medical School. Since 2015, she has headed the Max Planck Institute for Infection Biology in Berlin, while continuing to visit at the University of Umeå.

 

CONTRIBUTION

Speech

Biomedicine 9th edition

Micro interview

'The challenge is to develop CRISPR/Cas9 as a therapy for genetic disorders'

Francisco Martínez Mojica Jennifer Doudna, and Emmanuelle Charpentier are the instigators of one of the most impactful successes in modern science: a technology known as CRISPR, born from basic research of the purest kind – driven wholly by the spirit of inquiry – which facilitates genome modification with an unprecedented precision. The findings of Charpentier, Doudna and Martínez Mojica were instrumental in arriving at this technique, which allows to ‘cut and paste’ DNA sequences far more efficiently than with earlier methods, and it is for this achievement that the three now receive the Frontiers of Knowledge Award in Biomedicine.

The changes that CRISPR has wrought in the lives of its ‘parents’ are proportional to those it has ignited across the biology field, and those it may bring about in the whole of society in the not too distant future. Use of the technique, full name CRISPR/Cas9, continues to spread like wildfire.

In 2005, Francisco J. Martínez Mojica (Elche, Spain; 1963) published the discovery that ushered in the CRISPR revolution. In June 2012, Emmanuelle Charpentier and Jennifer Doudna (Washington DC, United States; 1964) found out how to use it to cut and paste DNA. And just a few months later, in what Doudna describes as an indication of ‘the coming tsunami,’ there were a dozen groups exploring the technique. Now thousands of laboratories around the world have CRISPR/Cas9 as part of their arsenal, and tests have even begun on its application in humans as a treatment for various types of cancer. In the history of science, it is hard to find cases of such a swift journey from the lab bench to the patient.

The starting point was curiosity. Francisco Juan Martínez Mojica is a microbiologist at the University of Alicante (Spain). In 1989, while working on a project to measure water quality along the region’s beaches, he began his PhD thesis on a microorganism isolated in the salt marshes of Santa Pola, ‘Haloferax mediterranei’. Mojica observed something strange in its genome: a series of genetic sequences repeating at regular intervals. There was nothing in the scientific literature to explain this oddity, and Mojica, intrigued, had to wait to have his own laboratory before trying to find out. Unable to obtain specific funding – ‘understandably,’ he concedes, given the ‘elementary nature of a project that could go anywhere at all’ – the young microbiologist began sifting through genomic databases, and discovered that regularly spaced repeat sequences occurred abundantly throughout the microbial world. This hinted at ‘major biological relevance.’ And Mojica’s curiosity became obsession.

The ‘happiest moment by far’ in Mojica’s scientific life came in 2003, when he finally uncovered the true nature of CRISPR: a defense mechanism microorganisms use to fend off viruses, something whose existence was entirely unsuspected. Mojica realized that the spaces between the repeat sequences carried fragments of the aggressor species’ genome; molecular signatures that could be recognized if they attacked again. In other words, a genetic vaccine. “The discovery that microorganisms, like us, are equipped with a defense system was just astounding,” Mojica recalls. The finding was not published until 2005, after leading journals like ‘Nature’ and ‘PNAS’ rejected the paper without sending it out for review.

Numerous groups immediately began competing to elucidate CRISPR’s exact mode of functioning. Charpentier, now at the Max Planck Institute for Infection Biology (Berlin, Germany) and the University of Umeå (Sweden), identified a key molecule in the CRISPR/ Cas9 system. Her attempts to solve its three-dimensional structure brought her into contact with Doudna, a reputed expert at the University of California, Berkeley (United States), and the two decided to join forces. In 2012 they managed to artificially reproduce the system, showing, as Charpentier explains, that it is “a powerful genome-editing tool that can be programmed to recognize any fragment of DNA.”

In nature, CRISPR/Cas9 destroys the attackers by slicing their DNA, with the Cas9 enzyme as the molecular scissors. In the lab, the viral DNA that CRISPR uses to recognize the enemy is replaced by another guide fragment, which steers the scissors to a specific genome region. The result is a technique that not only cuts DNA with exquisite precision, but also pastes it back in, along with new sequences if so desired.

The relative ease and superior effectiveness of the technique is the secret of its success, and also what keeps Doudna awake at night: What if it were used in germ cells or human embryos, to create heritable alterations? The scientist has become an active promoter of education and debate about the applications of genome editing, after “long sleepless nights wondering if I should stay clear of the ethical storm around the technology I helped create.”